Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

The race for dominance in weight-loss and diabetes treatments has reached a fever pitch. Investors choosing between Eli Lilly and (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) face a difficult decision in 2026.

Eli Lilly leads with a diverse U.S. portfolio and rapid expansion into metabolic health. Novo Nordisk remains a global powerhouse in insulin and obesity care, leveraging decades of specialized expertise. Both companies are currently capitalizing on the massive demand for GLP-1 medications, making them the primary contenders in the modern healthcare landscape.

The case for Eli Lilly and

Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical stocks globally, focusing on high-growth areas like oncology and immunology. It relies heavily on wholesale distributors, including McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). Customer concentration like this adds a layer of risk to the business, as these three major partners handle a significant share of its distribution and product logistics.

In FY 2025, revenue reached nearly $65.2 billion, representing a significant 44.7% increase over the previous year. This surge helped drive net income to roughly $20.6 billion, fueled by high demand for its newest metabolic treatments. The company reported a healthy net margin of approximately 31.7% for the period, indicating its ability to convert sales into profit effectively.

Based on its December 2025 balance sheet, the debt-to-equity ratio is roughly 1.6x, a metric that compares total liabilities to shareholder equity. The current ratio, which measures the ability to cover short-term debts with liquid assets, is approximately 1.6x. Free cash flow for FY 2025 was close to $9.0 billion, which represents cash from operations minus capital expenditures.

The case for Novo Nordisk A/S

In its latest annual report, filed for 2025, Novo Nordisk highlighted its focus on chronic diseases like diabetes and obesity. The company operates in a specialized niche within the healthcare sector, where it maintains deep expertise and a long history of innovation. While it does not disclose specific major customer concentrations in its public filings, it maintains a massive international distribution network that reaches patients in over 50 countries.

In FY 2025, revenue reached nearly $46.4 billion, reflecting approximately 6.4% growth over the previous 12-month period. Net income for the fiscal year was roughly $15.4 billion. The company maintained a strong net margin of approximately 33.1%, showing consistent profitability across its various global operations and therapeutic segments.

As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.7x. The current ratio is approximately 0.8x, indicating a tighter liquidity position in meeting short-term obligations such as bills and payroll. Free cash flow for the period was close to $4.3 billion, the cash remaining after the company funds its essential capital investments and infrastructure.

Risk profile comparison

Eli Lilly faces high research and development failure rates and significant revenue concentration in just a few key products. Pricing pressures from the Inflation Reduction Act also threaten future revenue. Additionally, the company must defend its intellectual property against generic manufacturers and manage complex cybersecurity threats to its clinical data.

Novo Nordisk navigates intense global competition and regulatory hurdles across multiple international markets. The company faces ongoing pressure to maintain its market share in the crowded diabetes space while scaling production for its obesity drugs. Any supply chain disruptions or safety concerns regarding its core medications could impact its financial performance.

Valuation comparison

Novo Nordisk currently appears significantly cheaper than Eli Lilly based on its Forward P/E and its P/S ratio. This latter metric compares the company's market value against its sales over the past twelve months.

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

Which stock would I buy in 2026?

To compare Eli Lilly and Novo Nordisk, investors should consider a few key factors. Let's have a look at them and see what that tells us about each stock.

First, there's growth. Here, Eli Lilly easily wins the head-to-head matchup. Lilly's revenue has skyrocketed in recent years, from around $30 billion in 2023 to nearly $80 billion. The company has averaged 40% year-over-year revenue growth over the last three years. Novo Nordisk, on the other hand, has grown moderately. Revenue has increased from approximately $30 billion in 2023 to about $51 billion. Its three-year growth rate has averaged 21% -- quite respectable, but a far cry from Eli Lilly's.

Another factor to consider is profitability. Here again, Lilly comes out on top. Lilly's current operating margin is 49.7%, having soared from around 25% in 2021. Novo Nordisk, meanwhile, has seen no significant margin improvement, despite its other progress. Operating margin is 45.4%, only slightly higher than its 10-year average of 42.9%.

Two final factors to weigh are income potential and valuation. Here, Novo Nordisk shines. Novo Nordisk stock boasts a dividend yield of 4.8%, while Lilly sports a 0.6% yield. As for valuation, Novo Nordisk again comes out on top. Both its forward P/E and P/S ratios are roughly 3x lower than Eli Lilly's.

To sum up, Eli Lilly and Novo Nordisk are both companies riding the growth of GLP-1 medications. However, their respective stocks are far from twins. Eli Lilly is growing much faster, and its overall profitability has skyrocketed in recent years. Novo Nordisk, by contrast, has grown steadily, but its profit margins remain largely stable. Yet, income-focused investors may be drawn to its impressive dividend yield and more modest valuation. As a growth-oriented investor, I am more drawn to Eli Lilly stock, given its exceptional growth and its strategy to introduce next-generation oral pills to lengthen its weight loss drug runway for many years to come.

Jake Lerch has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.